Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors Alentis raises $181.4M series D financing to advance Claudin-1 ADCs for solid tumors Alentis Corporate Video Featuring CEO Roberto Iacone and founder Thomas Baumert Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma Alentis Family Event 2023 impression Alentis Therapeutics presents ALE.F02 data for organ fibrosis at the European Respiratory Society International Congress ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1 ALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY
